Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies
Open Access
- 9 March 2023
- journal article
- review article
- Published by Taylor & Francis in Hematology
- Vol. 28 (1) , 2181749
Abstract
Background: Inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been used in the treatment of relapsed and refractory Hodgkin's lymphoma (R/R HL) recently. To further understand the safety and efficacy of PD-1/PD-L1 inhibitors in R/R HL, we conducted this meta-analysis. Methods: Databases and the Clinical Registration Platforms have been systematically searched for related studies by March 2022. For safety analysis, the incidence and exhibition of any grade and grade 3 or higher adverse effects (AEs) were evaluated. Besides, severe AEs (SAEs), treatment-related deaths, and AEs leading to treatment discontinuation were summarized. The overall response rate (ORR), complete response (CR) rate, partial response (PR) rate, progression-free survival (PFS), overall survival (OS), and duration of response (DOR) were calculated for efficacy analysis. All processes were implemented mainly through the package Meta and MetaSurv of software R 4.1.2. Results: Overall 20 studies and 1440 patients were enrolled. The pooled incidence of any grade and grade 3 or higher AEs were 92% and 26%, respectively. The pooled ORR, CR rate and PR rate were 79%, 44% and 34%, respectively. The most common AEs were neuropathy (29%), nausea (27%), pyrexia (26%), and leukopenia (25%), and the most common grade 3 or higher AEs included leukopenia (10%), infusion reaction (8%), weight gain (3%), and neutropenia (2.7%). In survival analysis, pembrolizumab monotherapy appeared to perform better compared to nivolumab monotherapy. Conclusions: PD-1/PD-L1 inhibitors show promising efficacy and tolerable AEs in the treatment of R/R HL.Keywords
Funding Information
- The key research and development program of Shandong Province (No. 2019JZZY011115 and 2021CXGC011101)
- Shandong University
This publication has 54 references indexed in Scilit:
- PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical CourseClinical Cancer Research, 2016
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyJournal of Clinical Oncology, 2016
- Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient programCritical Reviews in Oncology/Hematology, 2016
- Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomesAnnals of Oncology, 2016
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterJournal of Clinical Oncology, 2015
- Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effectsStatistics in Medicine, 2014
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- Epidemiology Of Hodgkin's disease: a reviewHematological Oncology, 2004
- Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trialThe Lancet, 2002